TY  - JOUR
AU  - Bonassi, Stefano
AU  - Ceppi, Marcello
AU  - Møller, Peter
AU  - Azqueta, Amaya
AU  - Milić, Mirta
AU  - Monica, Neri
AU  - Brunborg, Gunnar
AU  - Godschalk, Roger
AU  - Koppen, Gudrun
AU  - Langie, Sabine A. S.
AU  - Teixeira, João Paulo
AU  - Bruzzone, , Marco
AU  - Da Silva, Juliana
AU  - Benedetti, Danieli
AU  - Cavallo, Delia
AU  - Ursini, Cinzia Lucia
AU  - Giovannelli, Lisa
AU  - Moretti, Silvia
AU  - Riso, Patrizia
AU  - Del Bo’, Cristian
AU  - Russo, Patrizia
AU  - Dobrzyńska, , Malgorzata
AU  - Goroshinskaya, Irina A.
AU  - Surikova, Ekaterina I.
AU  - Staruchova, Marta
AU  - Barančokova, Magdalena
AU  - Volkovova, Katarina
AU  - Kažimirova, Alena
AU  - Smolkova, Bozena
AU  - Laffon, Blanca
AU  - Valdiglesias, Vanessa
AU  - Pastor, Susana
AU  - Marcos, Ricard
AU  - Hernández, Alba
AU  - Gajski, Goran
AU  - Spremo-Potparević, Biljana
AU  - Živković, Lada
AU  - Boutet-Robinet, Elisa
AU  - Perdry, Hervé
AU  - Lebailly, Pierre
AU  - Perez, Carlos L.
AU  - Basaran, Nursen
AU  - Nemeth, , Zsuzsanna
AU  - Safar, Anna
AU  - Dusinska, Maria
AU  - Collins, Andrew
AU  - Anderson, Diana
AU  - Andrade, Vanessa
AU  - Pereira, Cristiana Costa
AU  - Costa, Solange
AU  - Gutzkow, Kristine B.
AU  - Ladeira, Carina
AU  - Moretti, Massimo
AU  - Costa, Carla
AU  - Orlow, Irene
AU  - Rojas, Emilio
AU  - Pourrut, Bertrand
AU  - Kruszewski, Marcin
AU  - Knasmueller, Siegfried
AU  - Shaposhnikov, Sergey
AU  - Žegura, Bojana
AU  - Stopper, Helga
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3944
AB  - The comet assay or single cell gel electrophoresis, is the most common method used to measure strand breaks and a variety of other DNA lesions in human populations. To estimate the risk of overall mortality, mortality by cause, and cancer incidence associated to DNA damage, a cohort of 2,403 healthy individuals (25,978 person-years) screened in 16 laboratories using the comet assay between 1996 and 2016 was followed-up. Kaplan–Meier analysis indicated a worse overall survival in the medium and high tertile of DNA damage (p < 0.001). The effect of DNA damage on survival was modelled according to Cox proportional hazard regression model. The adjusted hazard ratio (HR) was 1.42 (1.06–1.90) for overall mortality, and 1.94 (1.04–3.59) for diseases of the circulatory system in subjects with the highest tertile of DNA damage. The findings of this study provide epidemiological evidence encouraging the implementation of the comet assay in preventive strategies for non-communicable diseases.
PB  - Nature Research
T2  - Scientific Reports
T1  - DNA damage in circulating leukocytes measured with the comet assay may predict the risk of death
VL  - 11
IS  - 1
DO  - 10.1038/s41598-021-95976-7
ER  - 

@article{
author = "Bonassi, Stefano and Ceppi, Marcello and Møller, Peter and Azqueta, Amaya and Milić, Mirta and Monica, Neri and Brunborg, Gunnar and Godschalk, Roger and Koppen, Gudrun and Langie, Sabine A. S. and Teixeira, João Paulo and Bruzzone, , Marco and Da Silva, Juliana and Benedetti, Danieli and Cavallo, Delia and Ursini, Cinzia Lucia and Giovannelli, Lisa and Moretti, Silvia and Riso, Patrizia and Del Bo’, Cristian and Russo, Patrizia and Dobrzyńska, , Malgorzata and Goroshinskaya, Irina A. and Surikova, Ekaterina I. and Staruchova, Marta and Barančokova, Magdalena and Volkovova, Katarina and Kažimirova, Alena and Smolkova, Bozena and Laffon, Blanca and Valdiglesias, Vanessa and Pastor, Susana and Marcos, Ricard and Hernández, Alba and Gajski, Goran and Spremo-Potparević, Biljana and Živković, Lada and Boutet-Robinet, Elisa and Perdry, Hervé and Lebailly, Pierre and Perez, Carlos L. and Basaran, Nursen and Nemeth, , Zsuzsanna and Safar, Anna and Dusinska, Maria and Collins, Andrew and Anderson, Diana and Andrade, Vanessa and Pereira, Cristiana Costa and Costa, Solange and Gutzkow, Kristine B. and Ladeira, Carina and Moretti, Massimo and Costa, Carla and Orlow, Irene and Rojas, Emilio and Pourrut, Bertrand and Kruszewski, Marcin and Knasmueller, Siegfried and Shaposhnikov, Sergey and Žegura, Bojana and Stopper, Helga",
year = "2021",
abstract = "The comet assay or single cell gel electrophoresis, is the most common method used to measure strand breaks and a variety of other DNA lesions in human populations. To estimate the risk of overall mortality, mortality by cause, and cancer incidence associated to DNA damage, a cohort of 2,403 healthy individuals (25,978 person-years) screened in 16 laboratories using the comet assay between 1996 and 2016 was followed-up. Kaplan–Meier analysis indicated a worse overall survival in the medium and high tertile of DNA damage (p < 0.001). The effect of DNA damage on survival was modelled according to Cox proportional hazard regression model. The adjusted hazard ratio (HR) was 1.42 (1.06–1.90) for overall mortality, and 1.94 (1.04–3.59) for diseases of the circulatory system in subjects with the highest tertile of DNA damage. The findings of this study provide epidemiological evidence encouraging the implementation of the comet assay in preventive strategies for non-communicable diseases.",
publisher = "Nature Research",
journal = "Scientific Reports",
title = "DNA damage in circulating leukocytes measured with the comet assay may predict the risk of death",
volume = "11",
number = "1",
doi = "10.1038/s41598-021-95976-7"
}

Bonassi, S., Ceppi, M., Møller, P., Azqueta, A., Milić, M., Monica, N., Brunborg, G., Godschalk, R., Koppen, G., Langie, S. A. S., Teixeira, J. P., Bruzzone, ,. M., Da Silva, J., Benedetti, D., Cavallo, D., Ursini, C. L., Giovannelli, L., Moretti, S., Riso, P., Del Bo’, C., Russo, P., Dobrzyńska, ,. M., Goroshinskaya, I. A., Surikova, E. I., Staruchova, M., Barančokova, M., Volkovova, K., Kažimirova, A., Smolkova, B., Laffon, B., Valdiglesias, V., Pastor, S., Marcos, R., Hernández, A., Gajski, G., Spremo-Potparević, B., Živković, L., Boutet-Robinet, E., Perdry, H., Lebailly, P., Perez, C. L., Basaran, N., Nemeth, ,. Z., Safar, A., Dusinska, M., Collins, A., Anderson, D., Andrade, V., Pereira, C. C., Costa, S., Gutzkow, K. B., Ladeira, C., Moretti, M., Costa, C., Orlow, I., Rojas, E., Pourrut, B., Kruszewski, M., Knasmueller, S., Shaposhnikov, S., Žegura, B.,& Stopper, H.. (2021). DNA damage in circulating leukocytes measured with the comet assay may predict the risk of death. in Scientific Reports
Nature Research., 11(1).
https://doi.org/10.1038/s41598-021-95976-7

Bonassi S, Ceppi M, Møller P, Azqueta A, Milić M, Monica N, Brunborg G, Godschalk R, Koppen G, Langie SAS, Teixeira JP, Bruzzone ,M, Da Silva J, Benedetti D, Cavallo D, Ursini CL, Giovannelli L, Moretti S, Riso P, Del Bo’ C, Russo P, Dobrzyńska ,M, Goroshinskaya IA, Surikova EI, Staruchova M, Barančokova M, Volkovova K, Kažimirova A, Smolkova B, Laffon B, Valdiglesias V, Pastor S, Marcos R, Hernández A, Gajski G, Spremo-Potparević B, Živković L, Boutet-Robinet E, Perdry H, Lebailly P, Perez CL, Basaran N, Nemeth ,Z, Safar A, Dusinska M, Collins A, Anderson D, Andrade V, Pereira CC, Costa S, Gutzkow KB, Ladeira C, Moretti M, Costa C, Orlow I, Rojas E, Pourrut B, Kruszewski M, Knasmueller S, Shaposhnikov S, Žegura B, Stopper H. DNA damage in circulating leukocytes measured with the comet assay may predict the risk of death. in Scientific Reports. 2021;11(1).
doi:10.1038/s41598-021-95976-7 .

Bonassi, Stefano, Ceppi, Marcello, Møller, Peter, Azqueta, Amaya, Milić, Mirta, Monica, Neri, Brunborg, Gunnar, Godschalk, Roger, Koppen, Gudrun, Langie, Sabine A. S., Teixeira, João Paulo, Bruzzone, , Marco, Da Silva, Juliana, Benedetti, Danieli, Cavallo, Delia, Ursini, Cinzia Lucia, Giovannelli, Lisa, Moretti, Silvia, Riso, Patrizia, Del Bo’, Cristian, Russo, Patrizia, Dobrzyńska, , Malgorzata, Goroshinskaya, Irina A., Surikova, Ekaterina I., Staruchova, Marta, Barančokova, Magdalena, Volkovova, Katarina, Kažimirova, Alena, Smolkova, Bozena, Laffon, Blanca, Valdiglesias, Vanessa, Pastor, Susana, Marcos, Ricard, Hernández, Alba, Gajski, Goran, Spremo-Potparević, Biljana, Živković, Lada, Boutet-Robinet, Elisa, Perdry, Hervé, Lebailly, Pierre, Perez, Carlos L., Basaran, Nursen, Nemeth, , Zsuzsanna, Safar, Anna, Dusinska, Maria, Collins, Andrew, Anderson, Diana, Andrade, Vanessa, Pereira, Cristiana Costa, Costa, Solange, Gutzkow, Kristine B., Ladeira, Carina, Moretti, Massimo, Costa, Carla, Orlow, Irene, Rojas, Emilio, Pourrut, Bertrand, Kruszewski, Marcin, Knasmueller, Siegfried, Shaposhnikov, Sergey, Žegura, Bojana, Stopper, Helga, "DNA damage in circulating leukocytes measured with the comet assay may predict the risk of death" in Scientific Reports, 11, no. 1 (2021),
https://doi.org/10.1038/s41598-021-95976-7 . .

TY  - JOUR
AU  - Milić, Mirta
AU  - Ceppi, Marcello
AU  - Bruzzone, Marco
AU  - Azqueta, Amaya
AU  - Brunborg, Gunnar
AU  - Godschalk, Roger
AU  - Koppen, Gudrun
AU  - Langie, Sabine
AU  - Møller, Peter
AU  - Teixeira, João Paulo
AU  - Alija, Avdulla
AU  - Anderson, Diana
AU  - Andrade, Vanessa
AU  - Andreoli, Cristina
AU  - Asllani, Fisnik
AU  - Bangkoglu, Ezgi Eyluel
AU  - Barančoková, Magdalena
AU  - Basaran, Nursen
AU  - Boutet-Robinet, Elisa
AU  - Buschini, Annamaria
AU  - Cavallo, Delia
AU  - Costa Pereira, Cristiana
AU  - Costa, Carla
AU  - Costa, Solange
AU  - Da Silva, Juliana
AU  - Del Boˊ, Cristian
AU  - Dimitrijević Srećković, Vesna
AU  - Đelić, Ninoslav
AU  - Dobrzyńska, Malgorzata
AU  - Duračková, Zdenka
AU  - Dvořáková, Monika
AU  - Gajski, Goran
AU  - Galati, Serena
AU  - García Lima, Omar
AU  - Giovannelli, Lisa
AU  - Goroshinskaya, Irina A.
AU  - Grindel, Annemarie
AU  - Gutzkow, Kristine B.
AU  - Hernández, Alba
AU  - Hernández, Carlos
AU  - Holven, Kirsten B.
AU  - Ibero-Baraibar, Idoia
AU  - Ottestad, Inger
AU  - Kadioglu, Ela
AU  - Kažimirová, Alena
AU  - Kuznetsova, Elena
AU  - Ladeira, Carina
AU  - Laffon, Blanca
AU  - Lamonaca, Palma
AU  - Lebailly, Pierre
AU  - Louro, Henriqueta
AU  - Mandina Cardoso, Tania
AU  - Marcon, Francesca
AU  - Marcos, Ricard
AU  - Moretti, Massimo
AU  - Moretti, Silvia
AU  - Najafzadeh, Mojgan
AU  - Nemeth, Zsuzsanna
AU  - Neri, Monica
AU  - Novotna, Bozena
AU  - Orlow, Irene
AU  - Paduchova, Zuzana
AU  - Pastor, Susana
AU  - Perdry, Hervé
AU  - Spremo-Potparević, Biljana
AU  - Ramadhani, Dwi
AU  - Riso, Patrizia
AU  - Rohr, Paula
AU  - Rojas, Emilio
AU  - Rossner, Pavel
AU  - Safar, Anna
AU  - Sardas, Semra
AU  - Silva, Maria João
AU  - Sirota, Nikolay
AU  - Smolkova, Bozena
AU  - Staruchova, Marta
AU  - Stetina, Rudolf
AU  - Stopper, Helga
AU  - Surikova, Ekaterina I.
AU  - Ulven, Stine M.
AU  - Ursini, Cinzia Lucia
AU  - Valdiglesias, Vanessa
AU  - Valverde, Mahara
AU  - Vodicka, Pavel
AU  - Volkovova, Katarina
AU  - Wagner, Karl-Heinz
AU  - Živković, Lada
AU  - Dušinská, Maria
AU  - Collins, Andrew R.
AU  - Bonassi, Stefano
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3791
AB  - The alkaline comet assay, or single cell gel electrophoresis, is one of the most popular methods for assessing DNA damage in human population. One of the open issues concerning this assay is the identification of those factors that can explain the large inter-individual and inter-laboratory variation. International collaborative initiatives such as the hCOMET project - a COST Action launched in 2016 - represent a valuable tool to meet this challenge. The aims of hCOMET were to establish reference values for the level of DNA damage in humans, to investigate the effect of host factors, lifestyle and exposure to genotoxic agents, and to compare different sources of assay variability. A database of 19,320 subjects was generated, pooling data from 105 studies run by 44 laboratories in 26 countries between 1999 and 2019. A mixed random effect log-linear model, in parallel with a classic meta-analysis, was applied to take into account the extensive heterogeneity of data, due to descriptor, specimen and protocol variability. As a result of this analysis interquartile intervals of DNA strand breaks (which includes alkali-labile sites) were reported for tail intensity, tail length, and tail moment (comet assay descriptors). A small variation by age was reported in some datasets, suggesting higher DNA damage in oldest age-classes, while no effect could be shown for sex or smoking habit, although the lack of data on heavy smokers has still to be considered. Finally, highly significant differences in DNA damage were found for most exposures investigated in specific studies. In conclusion, these data, which confirm that DNA damage measured by the comet assay is an excellent biomarker of exposure in several conditions, may contribute to improving the quality of study design and to the standardization of results of the comet assay in human populations.
PB  - Elsevier B.V.
T2  - Mutation Research - Reviews in Mutation Research
T1  - The hCOMET project: International database comparison of results with the comet assay in human biomonitoring. Baseline frequency of DNA damage and effect of main confounders
VL  - 787
DO  - 10.1016/j.mrrev.2021.108371
ER  - 

@article{
author = "Milić, Mirta and Ceppi, Marcello and Bruzzone, Marco and Azqueta, Amaya and Brunborg, Gunnar and Godschalk, Roger and Koppen, Gudrun and Langie, Sabine and Møller, Peter and Teixeira, João Paulo and Alija, Avdulla and Anderson, Diana and Andrade, Vanessa and Andreoli, Cristina and Asllani, Fisnik and Bangkoglu, Ezgi Eyluel and Barančoková, Magdalena and Basaran, Nursen and Boutet-Robinet, Elisa and Buschini, Annamaria and Cavallo, Delia and Costa Pereira, Cristiana and Costa, Carla and Costa, Solange and Da Silva, Juliana and Del Boˊ, Cristian and Dimitrijević Srećković, Vesna and Đelić, Ninoslav and Dobrzyńska, Malgorzata and Duračková, Zdenka and Dvořáková, Monika and Gajski, Goran and Galati, Serena and García Lima, Omar and Giovannelli, Lisa and Goroshinskaya, Irina A. and Grindel, Annemarie and Gutzkow, Kristine B. and Hernández, Alba and Hernández, Carlos and Holven, Kirsten B. and Ibero-Baraibar, Idoia and Ottestad, Inger and Kadioglu, Ela and Kažimirová, Alena and Kuznetsova, Elena and Ladeira, Carina and Laffon, Blanca and Lamonaca, Palma and Lebailly, Pierre and Louro, Henriqueta and Mandina Cardoso, Tania and Marcon, Francesca and Marcos, Ricard and Moretti, Massimo and Moretti, Silvia and Najafzadeh, Mojgan and Nemeth, Zsuzsanna and Neri, Monica and Novotna, Bozena and Orlow, Irene and Paduchova, Zuzana and Pastor, Susana and Perdry, Hervé and Spremo-Potparević, Biljana and Ramadhani, Dwi and Riso, Patrizia and Rohr, Paula and Rojas, Emilio and Rossner, Pavel and Safar, Anna and Sardas, Semra and Silva, Maria João and Sirota, Nikolay and Smolkova, Bozena and Staruchova, Marta and Stetina, Rudolf and Stopper, Helga and Surikova, Ekaterina I. and Ulven, Stine M. and Ursini, Cinzia Lucia and Valdiglesias, Vanessa and Valverde, Mahara and Vodicka, Pavel and Volkovova, Katarina and Wagner, Karl-Heinz and Živković, Lada and Dušinská, Maria and Collins, Andrew R. and Bonassi, Stefano",
year = "2021",
abstract = "The alkaline comet assay, or single cell gel electrophoresis, is one of the most popular methods for assessing DNA damage in human population. One of the open issues concerning this assay is the identification of those factors that can explain the large inter-individual and inter-laboratory variation. International collaborative initiatives such as the hCOMET project - a COST Action launched in 2016 - represent a valuable tool to meet this challenge. The aims of hCOMET were to establish reference values for the level of DNA damage in humans, to investigate the effect of host factors, lifestyle and exposure to genotoxic agents, and to compare different sources of assay variability. A database of 19,320 subjects was generated, pooling data from 105 studies run by 44 laboratories in 26 countries between 1999 and 2019. A mixed random effect log-linear model, in parallel with a classic meta-analysis, was applied to take into account the extensive heterogeneity of data, due to descriptor, specimen and protocol variability. As a result of this analysis interquartile intervals of DNA strand breaks (which includes alkali-labile sites) were reported for tail intensity, tail length, and tail moment (comet assay descriptors). A small variation by age was reported in some datasets, suggesting higher DNA damage in oldest age-classes, while no effect could be shown for sex or smoking habit, although the lack of data on heavy smokers has still to be considered. Finally, highly significant differences in DNA damage were found for most exposures investigated in specific studies. In conclusion, these data, which confirm that DNA damage measured by the comet assay is an excellent biomarker of exposure in several conditions, may contribute to improving the quality of study design and to the standardization of results of the comet assay in human populations.",
publisher = "Elsevier B.V.",
journal = "Mutation Research - Reviews in Mutation Research",
title = "The hCOMET project: International database comparison of results with the comet assay in human biomonitoring. Baseline frequency of DNA damage and effect of main confounders",
volume = "787",
doi = "10.1016/j.mrrev.2021.108371"
}

Milić, M., Ceppi, M., Bruzzone, M., Azqueta, A., Brunborg, G., Godschalk, R., Koppen, G., Langie, S., Møller, P., Teixeira, J. P., Alija, A., Anderson, D., Andrade, V., Andreoli, C., Asllani, F., Bangkoglu, E. E., Barančoková, M., Basaran, N., Boutet-Robinet, E., Buschini, A., Cavallo, D., Costa Pereira, C., Costa, C., Costa, S., Da Silva, J., Del Boˊ, C., Dimitrijević Srećković, V., Đelić, N., Dobrzyńska, M., Duračková, Z., Dvořáková, M., Gajski, G., Galati, S., García Lima, O., Giovannelli, L., Goroshinskaya, I. A., Grindel, A., Gutzkow, K. B., Hernández, A., Hernández, C., Holven, K. B., Ibero-Baraibar, I., Ottestad, I., Kadioglu, E., Kažimirová, A., Kuznetsova, E., Ladeira, C., Laffon, B., Lamonaca, P., Lebailly, P., Louro, H., Mandina Cardoso, T., Marcon, F., Marcos, R., Moretti, M., Moretti, S., Najafzadeh, M., Nemeth, Z., Neri, M., Novotna, B., Orlow, I., Paduchova, Z., Pastor, S., Perdry, H., Spremo-Potparević, B., Ramadhani, D., Riso, P., Rohr, P., Rojas, E., Rossner, P., Safar, A., Sardas, S., Silva, M. J., Sirota, N., Smolkova, B., Staruchova, M., Stetina, R., Stopper, H., Surikova, E. I., Ulven, S. M., Ursini, C. L., Valdiglesias, V., Valverde, M., Vodicka, P., Volkovova, K., Wagner, K., Živković, L., Dušinská, M., Collins, A. R.,& Bonassi, S.. (2021). The hCOMET project: International database comparison of results with the comet assay in human biomonitoring. Baseline frequency of DNA damage and effect of main confounders. in Mutation Research - Reviews in Mutation Research
Elsevier B.V.., 787.
https://doi.org/10.1016/j.mrrev.2021.108371

Milić M, Ceppi M, Bruzzone M, Azqueta A, Brunborg G, Godschalk R, Koppen G, Langie S, Møller P, Teixeira JP, Alija A, Anderson D, Andrade V, Andreoli C, Asllani F, Bangkoglu EE, Barančoková M, Basaran N, Boutet-Robinet E, Buschini A, Cavallo D, Costa Pereira C, Costa C, Costa S, Da Silva J, Del Boˊ C, Dimitrijević Srećković V, Đelić N, Dobrzyńska M, Duračková Z, Dvořáková M, Gajski G, Galati S, García Lima O, Giovannelli L, Goroshinskaya IA, Grindel A, Gutzkow KB, Hernández A, Hernández C, Holven KB, Ibero-Baraibar I, Ottestad I, Kadioglu E, Kažimirová A, Kuznetsova E, Ladeira C, Laffon B, Lamonaca P, Lebailly P, Louro H, Mandina Cardoso T, Marcon F, Marcos R, Moretti M, Moretti S, Najafzadeh M, Nemeth Z, Neri M, Novotna B, Orlow I, Paduchova Z, Pastor S, Perdry H, Spremo-Potparević B, Ramadhani D, Riso P, Rohr P, Rojas E, Rossner P, Safar A, Sardas S, Silva MJ, Sirota N, Smolkova B, Staruchova M, Stetina R, Stopper H, Surikova EI, Ulven SM, Ursini CL, Valdiglesias V, Valverde M, Vodicka P, Volkovova K, Wagner K, Živković L, Dušinská M, Collins AR, Bonassi S. The hCOMET project: International database comparison of results with the comet assay in human biomonitoring. Baseline frequency of DNA damage and effect of main confounders. in Mutation Research - Reviews in Mutation Research. 2021;787.
doi:10.1016/j.mrrev.2021.108371 .

Milić, Mirta, Ceppi, Marcello, Bruzzone, Marco, Azqueta, Amaya, Brunborg, Gunnar, Godschalk, Roger, Koppen, Gudrun, Langie, Sabine, Møller, Peter, Teixeira, João Paulo, Alija, Avdulla, Anderson, Diana, Andrade, Vanessa, Andreoli, Cristina, Asllani, Fisnik, Bangkoglu, Ezgi Eyluel, Barančoková, Magdalena, Basaran, Nursen, Boutet-Robinet, Elisa, Buschini, Annamaria, Cavallo, Delia, Costa Pereira, Cristiana, Costa, Carla, Costa, Solange, Da Silva, Juliana, Del Boˊ, Cristian, Dimitrijević Srećković, Vesna, Đelić, Ninoslav, Dobrzyńska, Malgorzata, Duračková, Zdenka, Dvořáková, Monika, Gajski, Goran, Galati, Serena, García Lima, Omar, Giovannelli, Lisa, Goroshinskaya, Irina A., Grindel, Annemarie, Gutzkow, Kristine B., Hernández, Alba, Hernández, Carlos, Holven, Kirsten B., Ibero-Baraibar, Idoia, Ottestad, Inger, Kadioglu, Ela, Kažimirová, Alena, Kuznetsova, Elena, Ladeira, Carina, Laffon, Blanca, Lamonaca, Palma, Lebailly, Pierre, Louro, Henriqueta, Mandina Cardoso, Tania, Marcon, Francesca, Marcos, Ricard, Moretti, Massimo, Moretti, Silvia, Najafzadeh, Mojgan, Nemeth, Zsuzsanna, Neri, Monica, Novotna, Bozena, Orlow, Irene, Paduchova, Zuzana, Pastor, Susana, Perdry, Hervé, Spremo-Potparević, Biljana, Ramadhani, Dwi, Riso, Patrizia, Rohr, Paula, Rojas, Emilio, Rossner, Pavel, Safar, Anna, Sardas, Semra, Silva, Maria João, Sirota, Nikolay, Smolkova, Bozena, Staruchova, Marta, Stetina, Rudolf, Stopper, Helga, Surikova, Ekaterina I., Ulven, Stine M., Ursini, Cinzia Lucia, Valdiglesias, Vanessa, Valverde, Mahara, Vodicka, Pavel, Volkovova, Katarina, Wagner, Karl-Heinz, Živković, Lada, Dušinská, Maria, Collins, Andrew R., Bonassi, Stefano, "The hCOMET project: International database comparison of results with the comet assay in human biomonitoring. Baseline frequency of DNA damage and effect of main confounders" in Mutation Research - Reviews in Mutation Research, 787 (2021),
https://doi.org/10.1016/j.mrrev.2021.108371 . .

TY  - JOUR
AU  - Fialova, Daniela
AU  - Laffon, Blanca
AU  - Marinković, Valentina
AU  - Tasić, Ljiljana
AU  - Doro, Peter
AU  - Soos, Gyongyver
AU  - Mota, Jorge
AU  - Dogan, Soner
AU  - Brkić, Jovana
AU  - Teixeira, Joao Paulo
AU  - Valdiglesias, Vanessa
AU  - Costa, Solange
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3360
AB  - IntroductionThe importance of rational drug therapy is increasing with the aging of the population. Since one of the main reasons for inappropriate drug prescribing is also the age-blind approach, which results in ageist practices, this narrative literature review focuses on the description of the main barriers related to insufficient individualization of drug regimens associated with such age-blind approaches.MethodologyA narrative literature review using the PubMed, WoS, Embase, and Scopus databases was conducted by the EU COST Action IS1402. Experts in different scientific fields from six countries (the Czech Republic, Spain, Portugal, Hungary, Serbia, and Turkey) worked in four specific areas: (1) underrepresentation of older adults in clinical trials and clinical and ethical consequences; (2) insufficient consideration of age-related changes and geriatric frailty in the evaluation of the therapeutic value of drugs; (3) frequent prescribing of potentially inappropriate medications (PIMs); and (4) frequent underuse of highly beneficial nonpharmacological strategies (e.g., exercise).ResultsOlder patients are underrepresented in clinical trials. Therefore, rigorous observational geriatric research is needed in order to obtain evidence on the real efficacy and safety of frequently used drugs, and e.g. developed geriatric scales and frailty indexes for claims databases should help to stimulate such research. The use of PIMs, unfortunately, is still highly prevalent in Europe: 22.6% in community-dwelling older patients and 49.0% in institutionalized older adults. Specific tests to detect the majority of age-related pharmacological changes are usually not available in everyday clinical practice, which limits the estimation of drug risks and possibilities to individualize drug therapy in geriatric patients before drug prescription. Moreover, the role of somenonpharmacological strategies is highly underestimated in older adultsin contrast to frequent use of polypharmacy. Among nonpharmacological strategies, particularly physical exercise was highly effective in reducing functional decline, frailty, and the risk of falls in the majority of clinicalstudies.ConclusionSeveral regulatory and clinical barriers contribute to insufficient knowledge on the therapeutic value of drugs in older patients, age-blind approach, and inappropriate prescribing. New clinical and observational research is needed, including data on comprehensive geriatric assessment and frailty, to document the real efficacy and safety of frequently used medications.
PB  - Springer Heidelberg, Heidelberg
T2  - European Journal of Clinical Pharmacology
T1  - Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strat
VL  - 75
IS  - 4
SP  - 451
EP  - 466
DO  - 10.1007/s00228-018-2603-5
ER  - 

@article{
author = "Fialova, Daniela and Laffon, Blanca and Marinković, Valentina and Tasić, Ljiljana and Doro, Peter and Soos, Gyongyver and Mota, Jorge and Dogan, Soner and Brkić, Jovana and Teixeira, Joao Paulo and Valdiglesias, Vanessa and Costa, Solange",
year = "2019",
abstract = "IntroductionThe importance of rational drug therapy is increasing with the aging of the population. Since one of the main reasons for inappropriate drug prescribing is also the age-blind approach, which results in ageist practices, this narrative literature review focuses on the description of the main barriers related to insufficient individualization of drug regimens associated with such age-blind approaches.MethodologyA narrative literature review using the PubMed, WoS, Embase, and Scopus databases was conducted by the EU COST Action IS1402. Experts in different scientific fields from six countries (the Czech Republic, Spain, Portugal, Hungary, Serbia, and Turkey) worked in four specific areas: (1) underrepresentation of older adults in clinical trials and clinical and ethical consequences; (2) insufficient consideration of age-related changes and geriatric frailty in the evaluation of the therapeutic value of drugs; (3) frequent prescribing of potentially inappropriate medications (PIMs); and (4) frequent underuse of highly beneficial nonpharmacological strategies (e.g., exercise).ResultsOlder patients are underrepresented in clinical trials. Therefore, rigorous observational geriatric research is needed in order to obtain evidence on the real efficacy and safety of frequently used drugs, and e.g. developed geriatric scales and frailty indexes for claims databases should help to stimulate such research. The use of PIMs, unfortunately, is still highly prevalent in Europe: 22.6% in community-dwelling older patients and 49.0% in institutionalized older adults. Specific tests to detect the majority of age-related pharmacological changes are usually not available in everyday clinical practice, which limits the estimation of drug risks and possibilities to individualize drug therapy in geriatric patients before drug prescription. Moreover, the role of somenonpharmacological strategies is highly underestimated in older adultsin contrast to frequent use of polypharmacy. Among nonpharmacological strategies, particularly physical exercise was highly effective in reducing functional decline, frailty, and the risk of falls in the majority of clinicalstudies.ConclusionSeveral regulatory and clinical barriers contribute to insufficient knowledge on the therapeutic value of drugs in older patients, age-blind approach, and inappropriate prescribing. New clinical and observational research is needed, including data on comprehensive geriatric assessment and frailty, to document the real efficacy and safety of frequently used medications.",
publisher = "Springer Heidelberg, Heidelberg",
journal = "European Journal of Clinical Pharmacology",
title = "Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strat",
volume = "75",
number = "4",
pages = "451-466",
doi = "10.1007/s00228-018-2603-5"
}

Fialova, D., Laffon, B., Marinković, V., Tasić, L., Doro, P., Soos, G., Mota, J., Dogan, S., Brkić, J., Teixeira, J. P., Valdiglesias, V.,& Costa, S.. (2019). Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strat. in European Journal of Clinical Pharmacology
Springer Heidelberg, Heidelberg., 75(4), 451-466.
https://doi.org/10.1007/s00228-018-2603-5

Fialova D, Laffon B, Marinković V, Tasić L, Doro P, Soos G, Mota J, Dogan S, Brkić J, Teixeira JP, Valdiglesias V, Costa S. Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strat. in European Journal of Clinical Pharmacology. 2019;75(4):451-466.
doi:10.1007/s00228-018-2603-5 .

Fialova, Daniela, Laffon, Blanca, Marinković, Valentina, Tasić, Ljiljana, Doro, Peter, Soos, Gyongyver, Mota, Jorge, Dogan, Soner, Brkić, Jovana, Teixeira, Joao Paulo, Valdiglesias, Vanessa, Costa, Solange, "Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strat" in European Journal of Clinical Pharmacology, 75, no. 4 (2019):451-466,
https://doi.org/10.1007/s00228-018-2603-5 . .

TY  - JOUR
AU  - Fialova, Daniela
AU  - Brkić, Jovana
AU  - Laffon, Blanca
AU  - Reissigova, Jindra
AU  - Gresakova, Silvia
AU  - Dogan, Soner
AU  - Doro, Peter
AU  - Tasić, Ljiljana
AU  - Marinković, Valentina
AU  - Valdiglesias, Vanessa
AU  - Costa, Solange
AU  - Kostriba, Jan
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3264
AB  - Background: The European Union (EU)(7)-PIM (potentially inappropriate medication) list presents the most comprehensive and up-to-date tool for evaluation of PIM prescribing in Europe; however, several country-specific studies have documented lower specificity of this list on pharmaceutical markets of some countries. The aim of our study was to describe approval rates and marketing of PIMs stated by EU(7)-PIM criteria in six EU countries [in comparison with the American Geriatric Society (AGS) Beers 2015 criteria]. Methods: Research teams of six EU countries (Czech Republic, Spain, Portugal, Serbia, Hungary and Turkey) participated in this study conducted by WG1b EU COST Action IS1402 group in the period October 2015-November 2018. Data on approval rates of PIMs and their availability on pharmaceutical markets have been obtained from databases of national drug-regulatory institutes and up-to-date drug compendia. The EU(7)-PIM list and AGS Beers 2015 Criteria (Section 1) were applied. Results: PIMs from EU(7)-PIM list were approved for clinical use more often than those from the AGS Beers 2015 criteria (Section 1). Approval rates for EU(7)-PIMs ranged from 42.8% in Serbia to 71.4% in Spain (for AGS criteria only from 36.4% to 65.1%, respectively). Higher percentages of approved PIMs were documented in Spain (71.4%), Portugal (67.1%) and Turkey (67.5%), lower in Hungary (55.5%), Czech Republic (50.2%) and Serbia (42.8%). The majority of approved PIMs were also currently marketed in all countries except in Turkey (19.8-21.7% not marketed PIMs) and less than 20% of PIMs were available as over-the-counter medications (except in Turkey, 46.4-48.1%). Conclusions: The EU(7)-PIM list was created for utilization in European studies; however, applicability of this list is still limited in some countries, particularly in Eastern and Central Europe. The EU project EUROAGEISM H2020 (2017-2021) that focuses on PIM prescribing and regulatory measures in Central and Eastern European countries must consider these limits.
PB  - Sage Publications Ltd, London
T2  - Therapeutic Advances in Drug Safet
T1  - Applicability of EU(7)-PIM criteria in cross-national studies in European countries
VL  - 10
DO  - 10.1177/2042098619854014
ER  - 

@article{
author = "Fialova, Daniela and Brkić, Jovana and Laffon, Blanca and Reissigova, Jindra and Gresakova, Silvia and Dogan, Soner and Doro, Peter and Tasić, Ljiljana and Marinković, Valentina and Valdiglesias, Vanessa and Costa, Solange and Kostriba, Jan",
year = "2019",
abstract = "Background: The European Union (EU)(7)-PIM (potentially inappropriate medication) list presents the most comprehensive and up-to-date tool for evaluation of PIM prescribing in Europe; however, several country-specific studies have documented lower specificity of this list on pharmaceutical markets of some countries. The aim of our study was to describe approval rates and marketing of PIMs stated by EU(7)-PIM criteria in six EU countries [in comparison with the American Geriatric Society (AGS) Beers 2015 criteria]. Methods: Research teams of six EU countries (Czech Republic, Spain, Portugal, Serbia, Hungary and Turkey) participated in this study conducted by WG1b EU COST Action IS1402 group in the period October 2015-November 2018. Data on approval rates of PIMs and their availability on pharmaceutical markets have been obtained from databases of national drug-regulatory institutes and up-to-date drug compendia. The EU(7)-PIM list and AGS Beers 2015 Criteria (Section 1) were applied. Results: PIMs from EU(7)-PIM list were approved for clinical use more often than those from the AGS Beers 2015 criteria (Section 1). Approval rates for EU(7)-PIMs ranged from 42.8% in Serbia to 71.4% in Spain (for AGS criteria only from 36.4% to 65.1%, respectively). Higher percentages of approved PIMs were documented in Spain (71.4%), Portugal (67.1%) and Turkey (67.5%), lower in Hungary (55.5%), Czech Republic (50.2%) and Serbia (42.8%). The majority of approved PIMs were also currently marketed in all countries except in Turkey (19.8-21.7% not marketed PIMs) and less than 20% of PIMs were available as over-the-counter medications (except in Turkey, 46.4-48.1%). Conclusions: The EU(7)-PIM list was created for utilization in European studies; however, applicability of this list is still limited in some countries, particularly in Eastern and Central Europe. The EU project EUROAGEISM H2020 (2017-2021) that focuses on PIM prescribing and regulatory measures in Central and Eastern European countries must consider these limits.",
publisher = "Sage Publications Ltd, London",
journal = "Therapeutic Advances in Drug Safet",
title = "Applicability of EU(7)-PIM criteria in cross-national studies in European countries",
volume = "10",
doi = "10.1177/2042098619854014"
}

Fialova, D., Brkić, J., Laffon, B., Reissigova, J., Gresakova, S., Dogan, S., Doro, P., Tasić, L., Marinković, V., Valdiglesias, V., Costa, S.,& Kostriba, J.. (2019). Applicability of EU(7)-PIM criteria in cross-national studies in European countries. in Therapeutic Advances in Drug Safet
Sage Publications Ltd, London., 10.
https://doi.org/10.1177/2042098619854014

Fialova D, Brkić J, Laffon B, Reissigova J, Gresakova S, Dogan S, Doro P, Tasić L, Marinković V, Valdiglesias V, Costa S, Kostriba J. Applicability of EU(7)-PIM criteria in cross-national studies in European countries. in Therapeutic Advances in Drug Safet. 2019;10.
doi:10.1177/2042098619854014 .

Fialova, Daniela, Brkić, Jovana, Laffon, Blanca, Reissigova, Jindra, Gresakova, Silvia, Dogan, Soner, Doro, Peter, Tasić, Ljiljana, Marinković, Valentina, Valdiglesias, Vanessa, Costa, Solange, Kostriba, Jan, "Applicability of EU(7)-PIM criteria in cross-national studies in European countries" in Therapeutic Advances in Drug Safet, 10 (2019),
https://doi.org/10.1177/2042098619854014 . .

TY  - CONF
AU  - Fialova, Daniela
AU  - Vysinova, Tereza
AU  - Gresakova, Silvia
AU  - Laffon-Deusdad, Blanca
AU  - Doro, Peter
AU  - Dogan, Soner
AU  - Costa, Solange
AU  - Valdiglesias, Vanessa
AU  - Brkić, Jovana
AU  - Marinković, Valentina
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2950
PB  - Springer, Dordrecht
C3  - International Journal of Clinical Pharmacy
T1  - Potentially inappropriate medications in the elderly and their different approval rates in countries participating in the EU COST Action 1402 initiative
VL  - 39
IS  - 1
SP  - 310
EP  - 311
DO  - 10.1007/s11096-016-0404-4
ER  - 

@conference{
author = "Fialova, Daniela and Vysinova, Tereza and Gresakova, Silvia and Laffon-Deusdad, Blanca and Doro, Peter and Dogan, Soner and Costa, Solange and Valdiglesias, Vanessa and Brkić, Jovana and Marinković, Valentina",
year = "2017",
publisher = "Springer, Dordrecht",
journal = "International Journal of Clinical Pharmacy",
title = "Potentially inappropriate medications in the elderly and their different approval rates in countries participating in the EU COST Action 1402 initiative",
volume = "39",
number = "1",
pages = "310-311",
doi = "10.1007/s11096-016-0404-4"
}

Fialova, D., Vysinova, T., Gresakova, S., Laffon-Deusdad, B., Doro, P., Dogan, S., Costa, S., Valdiglesias, V., Brkić, J.,& Marinković, V.. (2017). Potentially inappropriate medications in the elderly and their different approval rates in countries participating in the EU COST Action 1402 initiative. in International Journal of Clinical Pharmacy
Springer, Dordrecht., 39(1), 310-311.
https://doi.org/10.1007/s11096-016-0404-4

Fialova D, Vysinova T, Gresakova S, Laffon-Deusdad B, Doro P, Dogan S, Costa S, Valdiglesias V, Brkić J, Marinković V. Potentially inappropriate medications in the elderly and their different approval rates in countries participating in the EU COST Action 1402 initiative. in International Journal of Clinical Pharmacy. 2017;39(1):310-311.
doi:10.1007/s11096-016-0404-4 .

Fialova, Daniela, Vysinova, Tereza, Gresakova, Silvia, Laffon-Deusdad, Blanca, Doro, Peter, Dogan, Soner, Costa, Solange, Valdiglesias, Vanessa, Brkić, Jovana, Marinković, Valentina, "Potentially inappropriate medications in the elderly and their different approval rates in countries participating in the EU COST Action 1402 initiative" in International Journal of Clinical Pharmacy, 39, no. 1 (2017):310-311,
https://doi.org/10.1007/s11096-016-0404-4 . .